The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > LATEST
LATEST
-
REGULATORY JPA Wary of FPMAJ Pitch to Allow Non-Pharmacists as Drug Production Managers
May 21, 2024
-
REGULATORY Allow Use of OOS Autologous Cell Products via PMD Act Amendment: FIRM
May 21, 2024
-
REGULATORY Pharma Industry Wants “Internationally Harmonized” Rules under PMD Act
May 20, 2024
-
BUSINESS Towa, Sawai See Continued Growth in Japan in FY2024 amid New WPP Strategies
May 20, 2024
-
REGULATORY Novartis’ Fabhalta, Novo’s Awiqli, and More Up for PAFSC Review on May 31
May 20, 2024
-
BUSINESS Pfizer Rolls Out Single-Dose Version of COVID-19 Vaccine in Japan
May 20, 2024
-
BUSINESS Keytruda Gets Nod for Gastric, Biliary Tract Cancer in Japan
May 20, 2024
-
BUSINESS Prevymis Now Approved for CMV Prevention in Organ Transplant Recipients in Japan
May 20, 2024
-
BUSINESS Braftovi-Mektovi Combo Broadens Label to Thyroid Cancer: Ono
May 20, 2024
-
REGULATORY Expand Mixed-Billing Scheme, Use of Private Payers: LDP Healthcare Reform Team
May 20, 2024
-
BUSINESS Amylyx Pulls Out from Japan after ALS Trial Flop
May 20, 2024
-
REGULATORY MHLW’s Generic Industry Panel to Call for 5-Year Intensive Reform Period
April 26, 2024
-
REGULATORY PMDA Stepping Up Generic Compliance Inspections from August Approvals
April 16, 2024
-
BUSINESS 80%-Plus Doctors Seek In-Person Meetings with Reps: Lilly Survey
April 16, 2024
-
BUSINESS Meiji Reaffirms 2028 Launch Plan for New Vaccine Site as METI Grants Finalized
April 16, 2024
-
BUSINESS Nxera Grants Pivlaz’s Korean Commercial Rights to Handok
April 16, 2024
-
BUSINESS Vabysmo Set for 2025 Filing for Angioid Streaks after Japan Trial Success
April 16, 2024
-
BUSINESS Xofluza Approved for Pediatric Use in Taiwan: Shionogi
April 16, 2024
-
REGULATORY 14 Makers Picked for Health Minister-Championed Subsidy Program for Cough Meds, Essential Drugs
April 15, 2024
-
BUSINESS Fujifilm to Invest 180 Billion Yen to Bolster Biologic CDMO Biz in North America
April 15, 2024
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…